Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 37-44

  Campbell, Islay ^a   Moyana, Terence ^b   Carlsen, Svein ^a   Zheng, Changyu ^c   Xiang, Jim ^a,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d Saskatoon Cancer Center   (Canada)

Author keywords

Allogeneic major histocompatibility complex class I; Gene therapy; Recombinant adenovirus; Xenogeneic major histocompatibility complex class I

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CARCINOGENICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA TRANSFER; FEMALE; GENE THERAPY; HISTOCOMPATIBILITY GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

EID: 0033976809     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700116     Document Type: Article

References (34)

1. Townsend A, Bostin J, Gould K, Brownlee G. Cytotoxic T lymphocytes recognized influenza hemagglutinin that lacks a signal sequence. Nature. 1986;324:575-577.
2. Mandelboim O, Eisenbach L. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 1994;369:67-71.
3. McDougall C, Ngoi S, Goldman I, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 1990;50:8023-8027.
4. Eisenbach L, Feldman M. Tumor cell surface determinants in host immunity against metastases. Semin Cancer Biol. 1991;2:179-188.
5. b gene. Proc Natl Acad Sci USA. 1988;85:4463-4467.
6. Ostrand-Rosenberg S, Clements V, Thakur A, Cole G. Transfection of major histocompatibility complex class I and class II genes causes tumor rejection. J Immunogenet. 1989;16:343-349.
7. b gene in B16 cells correlates with suppression of liver metastases in triple immunodeficient mice. Cancer Res. 1992;52:4036-4041.
8. Hui K, Sim T, Foo T, Anne-Oei A. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol. 1989;143:3934-3853.
9. Gelber C, Plaksin D, Vadai E, Feldman M, Eisenbach L. Abolishment of metastases formation by murine tumor cells transfected with foreign H-2K genes. Cancer Res. 1989;49:2366-2373.
10. Plautz G, Yang Z, Wu B, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA. 1993;90:4645-4649.
11. Nabel G, Nabel E, Yang Z, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA. 90; 11307-11311.
12. Hui K, Chia T. Eradication of tumor growth via biolistic transformation with allogeneic MHC genes. Gene Ther. 1997;4:762-767.
13. Cole G, Clements V, Carcia E, Ostrand-Rosenberg S. Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proc Natl Acad Sci USA. 1987;84:8613-8617.
14. Mandelboim O, Vadai E, Feldman M, Eisenbach L. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther. 1995;2:757-765.
15. Wahl W, Strome S, Nabel G, et al. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene. J Immunother. 1995;17:1-11.
16. Yamada K, Sachs D, DerSimonian H. Human anti-porcine xenogeneic T cell response: evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol. 1995;155: 5249-5256.
17. Hock R, Reynold B, Tucker-McClung C, Kwok W. Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother. 1995;17:12-18.
18. Chen S, Chen X, Wang Y, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.
19. Nguyen D, Wiehle S, Koch P, et al. Delivery of p53 tumor suppressor gene into lung cancer cells by an adenovirus/ DNA complex. Cancer Gene Ther. 1997;4:191-198.
20. Mauceri H, Hanna N, Wayne J, et al. Tumor necrosis factor gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996;56: 4311-4314.
21. Carlsen S, Xie Y, Whitefield D, et al. Isoglobotetraosylceramide is a marker for highly metastatic cells in rat mammary adenocarcinomas. Cancer Res. 1993;53:2906-2911.
22. Xiang J, Moyana T, Matte G, et al. Establishment of a rat colonic carcinoma model for study of immunoreagents against the human associated TAG72 antigen. Cancer Biother Radiopharm. 1996;11:335-344.
23. Wright P, Zheng C, Moyana T, Xiang J. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-α induces significant tumor regression. Cancer Gene Ther. 1998;5:371-379.
24. Hellstrom K, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev. 1995;145:123-145.
25. Lucks P, Shearer G, Neudorf S, Gress R. The human anti-murine xenogeneic cytotoxic response: dependence on responder APCs. J Immunol. 1990;144:4548.
26. Alter B, Bach F. Cellular basis of the proliferative response of human T cells to mouse xenoantigens. J Exp Med. 1990;171:333.
27. Moses R, Pierson R, Winn H, Auchincloss H. Xenogeneic proliferation and lymphokine production are dependent on CD4 helper T cells and self antigen-presenting cells in the mouse. J Exp Med. 1990;172:567-575.
28. Wallgren A, Karlsson-Parra A, Korsgren O. The main infiltrating cell in xenograft rejection is a CD4 macrophage and not a T lymphocyte. Transplantation. 1995;60:594-601.
29. Mosmann T, Sad S. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol Today. 1996;17:138.
30. Croft M, Carter S, Swain S, Dutton R. Generation of polarized antigen-specific CDS effector populations: reciprocal action of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med. 1994;180:1715.
31. Lee P, Zheng D, McCaulay A, et al. T helper 2-dominant anti-lymphoma immune response is associated with fatal outcome. Blood. 1997;90:1611-1617.
32. Hu H, Urba W, Fox B. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998;161:3033-3041.
33. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996;56:694-699.
34. Nabel G, Chang A, Nabel E, et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther. 1994;5:57-77.